Medgend Icon







discontinued


Amitiza FDA Approved Drugs

AMITIZA [LubiprostoneC20H32F2O5]
RX
-
24mcg (oral capsule)
8mcg (oral capsule)
Sucampo Pharma LlcJan 31, 2006
  • Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
  • Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
  • Method for relieving or treating constipation in a human constipated patient.
  • Method for relieving or treating constipation in a patient with irritable bowel syndrome.
  • Method for relieving or treating constipation in a patient with opioid-induced constipation.
  • Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome.
  • Method for the long term treatment of chronic constipation in a human subject.
  • Method for treating constipation by opening cic channels in a mammalian subject.
  • Method for treating constipation in a patient with opioid-induced constipation by opening cic channels.
  • Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome.
  • Method for treating opioid-induced constipation.
  • Method of relieving or preventing constipation in a human constipated patient.
  • Method of relieving or preventing constipation in a human patient with opioid-induced constipation.
  • Method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic).
  • Method of treating constipation in a patient with irritable bowel syndrome.
  • Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient.
  • Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.